secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRADIMED CORP (IRMD)
CIK:        0001325618
Form:       8-K
Filed at:   2022-07-29T23:59:59+00:00
Accession:  0000898432-22-000500
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iRadimed reports record Q2 revenue of $12.7M; GAAP EPS $0.26; full-year guidance raised
--------------------------------------------------------------------------------

- Q2 revenue $12.7M vs $9.8M YoY (+30%); GAAP diluted EPS $0.26 vs $0.12; non-GAAP EPS $0.26.
- Q3 2022 guidance: revenue $13.1-13.3M, GAAP EPS $0.21-0.24, non-GAAP EPS $0.22-0.25.
- Full-year 2022 guidance raised: revenue $52.5-53.2M (from $51.4-52.2M), GAAP EPS $0.89-0.95 (from $0.82-0.90), non-GAAP EPS $0.96-1.03.
- Gross margin improved to 79.7% from 76.2%; domestic sales 85% of revenue.
- Q2 cash from operations $1.6M vs $3.6M YoY; orders exceeded shipments building backlog.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1325618/000089843222000500/0000898432-22-000500-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1325618/000089843222000500/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0000898432-22-000500

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer